NCT00290303View on ClinicalTrials.gov

Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

996

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Haemophilus Influenzae Type bDiphtheriaWhole Cell PertussisHepatitis BTetanus
Interventions
BIOLOGICAL

DTPw-HBV/Hib-MenAC conjugate vaccine

Trial Locations (3)

1000

GSK Investigational Site, Manila

1008

GSK Investigational Site, Sampaloc, Manila

1109

GSK Investigational Site, Quezon City

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00290303 - Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants | Biotech Hunter | Biotech Hunter